 GAINESVILLE, Fla., and CAMBRIDGE, Mass., Jan. 27, 2021 GLOBE NEWSWIRE -- Applied Genetic Technologies Corporation Nasdaq: AGTC, a biotechnology company conducting human clinical trials of adeno-associated virus AAV-based gene therapies for the treatment of rare diseases, today announced that it is offering to sell shares of its common stock and pre-funded warrants, together with accompanying warrants to purchase shares of its common stock in an underwritten public offering. All of the securities in the proposed offering are being sold by AGTC. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. 